Comments on the FDA’s Drug Supply Chain Security Act, an important area of focus for our Institute

September 2021

There is a need for end-to-end trust verification for the entire value chain to enhance patient safety, patient health, product quality, and product authenticity by reducing diversion, counterfeiting, profitability, and potential drug shortages. Read more about our proposed collaborative approach for helping secure the supply chain for prescription drugs using interoperable GS1 standards.